ESMO Media Releases

There is growing evidence that drugs approved for the treatment of breast cancer in women are also effective and well tolerated in men, according to the largest real-life study yet to investigate treatment and outcomes in men with breast cancer

Arbitrary age limits for participation prevent young patients from entering trials designed for their tumour type

Epigenetic therapy with histone deacetylase (HDAC) inhibitors is worth pursuing in hormone receptor positive advanced breast cancer, suggests a phase III trial (1) reported today at the ESMO 2018 Congress in Munich.

Targeting a common mutation in patients with hormone receptor positive (HR+) HER2 negative (HER2-)

Immunotherapy improves survival in some patients with metastatic triple negative breast cancer

Treatment with the cyclin dependent kinase (CDK) 4/6 inhibitor palbociclib achieves a clinically meaningful improvement in overall survival in patients with hormone receptor positive

Adjuvant treatment with the bone sparing drug zoledronic acid plus hormonal therapy with the aromatase inhibitor letrozole significantly increases disease-free survival

Biological medicines are responsible for some of the most promising innovations in cancer treatment

Immunotherapy has been a major breakthrough in oncology, with registered drugs now approved for use in an increasing number of tumour types

Chemotherapy is known to have a negative impact on the reproductive potential of young breast cancer patients. Its effects on women’s post-treatment fertility, however, are still poorly understood.

Most people with lung cancer are unaware of the benefits of regular exercise, yet new data show it can significantly reduce fatigue and improve well being.

Including exercise or sport as part of cancer care can significantly improve symptom management, quality of life and fitness during and after treatment, French researchers have concluded in two presentations to be reported at the ESMO 2018 Congress in Munich.